Diabetes With Preserved Renal Function Is an Independent Risk Factor for Renal Function Deterioration After Coronary Computed Tomography Angiography

Objectives Diabetes mellitus (DM) and high fasting glucose levels are reportedly risk factors for contrast-induced nephropathy after invasive coronary angiography in patients with renal dysfunction. Cystatin C (CyC) is a sensitive marker for detecting early impairment of renal function. Using CyC, we investigated whether DM would be a risk for worsening renal function after coronary computed tomography angiography (CCTA) in patients with preserved renal function. Methods Two hundred twenty-eight patients scheduled for CCTA were enrolled. The serum CyC at preprocedure and 1 day after procedure, urinary microalbumin at preprocedure, and oral fluid volume for 24 hours after procedure were measured. The percentage changes in CyC from preprocedure to 1 day after procedure (%CyC) were also calculated. Results Ninety-eight patients had DM. The %CyC and urinary microalbumin were significantly greater in DM patients than in non-DM patients. The percentage of patients showing a %CyC of 10% or greater was significantly greater in DM patients than in non-DM patients (27% vs 8%, P < 0.01). Using multivariate regression analysis, oral fluid volume and urinary microalbumin were independent predictors for a %CyC of 10% or greater in DM patients (&bgr; = − 0.428 [P < 0.0001] and &bgr; = 0.464 [P < 0.0001], respectively). Conclusions Diabetes mellitus is a risk factor for worsening changes in renal function after CCTA, even in patients with preserved renal function. In particular, elevated microalbuminuria and low oral fluid intake are high-risk factors for renal functional deterioration.

[1]  T. Murohara,et al.  Cystatin C: A Possible Sensitive Marker for Detecting Potential Kidney Injury After Computed Tomography Coronary Angiography , 2011, Journal of computer assisted tomography.

[2]  J. Roozbeh,et al.  Comparison of risk factors for contrast‐induced acute kidney injury between patients with and without diabetes , 2010, Hemodialysis international. International Symposium on Home Hemodialysis.

[3]  A. Colombo,et al.  Cystatin C and Contrast-Induced Acute Kidney Injury , 2010, Circulation.

[4]  J. Spertus,et al.  Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography. , 2010, Journal of the American College of Cardiology.

[5]  Yasuhiko Tomino,et al.  Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  T. Murohara,et al.  Feasibility of intravenous administration of landiolol hydrochloride for multislice computed tomography coronary angiography: initial experience. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[7]  J. Tumlin,et al.  Economic burden of contrast-induced nephropathy: implications for prevention strategies , 2007, Journal of medical economics.

[8]  Marco Valgimigli,et al.  Diagnostic performance of multislice spiral computed tomography of coronary arteries as compared with conventional invasive coronary angiography: a meta-analysis. , 2006, Journal of the American College of Cardiology.

[9]  Tetsuhiro Tanaka,et al.  High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway. , 2006, Journal of the American Society of Nephrology : JASN.

[10]  P. Stein,et al.  Multidetector computed tomography for the diagnosis of coronary artery disease: a systematic review. , 2006, The American journal of medicine.

[11]  G. Stone,et al.  Radiocontrast-Induced Acute Renal Failure—Impact beyond the Acute Phase Contrast-Induced Nephropathy after Percutaneous Coronary Interventions in Relation to Chronic Kidney Disease and Hemodynamic Variables. Am J Cardiol 95: 13–19, 2005 , 2006 .

[12]  P. Parfrey,et al.  Preventing Nephropathy Induced by Contrast Medium , 2006 .

[13]  Michele Meschi,et al.  Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  S. Wildermuth,et al.  Accuracy of MSCT coronary angiography with 64-slice technology: first experience. , 2005, European heart journal.

[15]  R. Nelson,et al.  Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. , 2005, Journal of the American Society of Nephrology : JASN.

[16]  A. Levin.  Cystatin C, Serum Creatinine, and Estimates of Kidney Function: Searching for Better Measures of Kidney Function and Cardiovascular Risk , 2005, Annals of Internal Medicine.

[17]  S. Rosen,et al.  Regional alterations in renal haemodynamics and oxygenation: a role in contrast medium-induced nephropathy. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  F. Veglia,et al.  Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. , 2004, Journal of the American College of Cardiology.

[19]  R. Gans,et al.  Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC. , 2004, Kidney international. Supplement.

[20]  Stephen Schroeder,et al.  Noninvasive detection of coronary lesions using 16-detector multislice spiral computed tomography technology: initial clinical results. , 2004, Journal of the American College of Cardiology.

[21]  Mario Plebani,et al.  Biochemistry and Clinical Role of Human Cystatin C , 2004, Critical reviews in clinical laboratory sciences.

[22]  C. Perlemoine,et al.  Interest of cystatin C in screening diabetic patients for early impairment of renal function. , 2003, Metabolism: clinical and experimental.

[23]  K. Kent,et al.  Percutaneous coronary intervention‐associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[24]  Pedro A. Lemos,et al.  Reliable Noninvasive Coronary Angiography With Fast Submillimeter Multislice Spiral Computed Tomography , 2002, Circulation.

[25]  V. Dharnidharka,et al.  Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  H. Gerstein,et al.  The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. , 1997, Archives of internal medicine.

[27]  A. Alzaid.  Microalbuminuria in Patients With NIDDM: An Overview , 1996, Diabetes Care.

[28]  P. Nilsson-ehle,et al.  Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. , 1994, Clinical chemistry.

[29]  P. Parfrey,et al.  Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. , 1989, The New England journal of medicine.

[30]  T. Murohara,et al.  Predictors of worsening renal function after computed tomography coronary angiography: assessed by cystatin C. , 2012, Journal of cardiovascular computed tomography.

[31]  D. Willems,et al.  Cystatin C for early detection of renal impairment in diabetes. , 2009, Clinical biochemistry.

[32]  R. Garrick.  Contrast-Induced Nephropathy After Percutaneous Coronary Interventions in Relation to Chronic Kidney Disease and Hemodynamic Variables , 2007 .